Business
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
Cyclin E1 molecular glue degraders (MGDs) represent a potential novel therapeutic approach by directly and selectively targeting a frequently amplified
About this update from Monte Rosa Therapeutics, Inc.
[{"type":"text","content":"Cyclin E1 molecular glue degraders (MGDs) represent a potential novel therapeutic approach by directly and selectively targeting a frequently amplified non-enzymatic driver oncogene relevant in multiple solid tumors Cyclin E1 MGD inhibited tumor growth in CCNE1-amplified cancer models in vivo BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the 36th EORTC-NCI-AACR Symposium (ENA 2024), taking place in Barcelona, Spain from October 23 to 25, on the potential of its cyclin E1 (CCNE1)-directed molecular glue degraders (MGDs) for the treatment of CCNE1-amplified solid tumors. CCNE1 is a well-validated oncogene that is amplified in multiple tumor types, but the corresponding cyclin E1 protein has traditionally been undruggable. The data being presented demonstrate that Monte Rosa’s MGD degrades cyclin E1 with a high level of selectivity, sparing other closely related proteins, including other cyclins, and cyclin-dependent kinases (CDKs). The data also showed that a cyclin E1-directed MGD led to downstream pathway inhibition and induced tumor growth suppression and regression preferentially in CCNE1-amplified and over-expressing tumor cell lines and xenograft models. The Company continues to perform preclinical research in order to progress the program towards a development candidate nomination. “Cyclin E1 (CCNE1) has long been a high interest yet undruggable oncology target. By directly and selectively targeting this frequently amplified non-enzymatic driver oncogene, cyclin E1 MGDs represent a potential paradigm shift and novel precision medicine approach,” said Sharon Townson, Ph.D., Chief Scientific Officer of Monte Rosa Therapeutics. “Our results demonstrate that our cyclin E1-targeted MGD drives highly selective and potent degradation of cyclin E1, which we believe is important because it could reduce toxicities associated with inhibition of closely related cyclins as well as CDKs. We believe these promising data support continued preclinical development and the potential of cyclin E1-directed MGDs as an important new therapeutic approach for various solid tumors, including ovarian, endometrial, gastric, breast, and other cancers...